MADISON, Wis., September 6, 2007 — Roche NimbleGen Inc., a fully integrated part of Roche Applied Science, today announced the addition of 4-plex eukaryotic gene expression analysis microarrays and services to its growing suite of genomic and epigenetic analysis tools.

The NimbleChip™ Multiplex Arrays enable researchers to simultaneously hybridize and analyze samples in four replicate arrays on a single slide to provide a high-performance yet cost-effective approach to gene expression analysis. Roche NimbleGen's unique ability to make long oligonucleotide probes (60mer) in combination with high density sub-arrays of 72,000 probes each provides comprehensive coverage of entire genomes with multiple probes per gene. The averaging of the results from multiple probes (typically 3-7 probes per gene) provides improved statistical confidence and can dramatically reduce the impact of inconsistent probe behavior, ensuring high specificity, sensitivity, and reproducibility compared to platforms that offer only one to two probes per gene.

Whole-genome designs are available in multiplex format for a broad range of species, including human, mouse, rat, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Arabidopsis thaliana, Caenorhabditis elegans, and Drosophila melanogaster. Researchers can also request custom gene expression arrays in the 4-plex format for any eukaryote with a well annotated genome.

“From the first experiment we found that the Roche NimbleGen multiplex platform was easy to use in a standard laboratory setting. The results are extremely reproducible, and control probes provide reliable identification of the samples loaded on each of the sub-arrays,” said beta collaborator Dr. Jason Lieb, assistant professor at the Carolina Center for Genome Sciences and The University of North Carolina, Chapel Hill. “We will certainly look to this platform as an economical way to perform many experiments in-house.”

Roche NimbleGen is a leading innovator, manufacturer, and supplier of a proprietary suite of DNA microarrays, consumables, instruments, and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by Roche NimbleGen's proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligo, high-density DNA microarrays with extreme flexibility. For more information about Roche NimbleGen, please visit the company’s website at www.nimblegen.com.

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolic disorders and diseases of the central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invests approximately 7 billion Swiss francs a year in R&D. Worldwide, the Group employs about 75,000 people. Additional information is available on the Internet at www.roche.com.

For more information, please contact

Roche NimbleGen, Inc.
Joleen Rau
Sr. Director, Marketing Communications
Phone (608) 218-7623
Email: jrau@nimblegen.com